한글목차

암로디핀 베실산염 세계 시장 규모는 2024년에 6억 9,088만 달러로 평가되었습니다. 2030년에는 12억 1,865만 달러에 달할 것으로 예상되며, 예측 기간 동안 4.25%의 연평균 복합 성장률(CAGR)을 보일 것으로 예측됩니다.

이 시장은 고혈압과 심혈관 질환의 유병률 증가로 인해 꾸준히 성장하고 있습니다. 널리 처방되는 칼슘 채널 차단제인 암로디핀베실산염은 고혈압과 협심증 관리에 필수적인 약물로 전 세계 심혈관 치료의 핵심입니다. 주요 시장 성장 촉진요인은 특히 고령화 사회에서 전 세계 고혈압 발병률 증가입니다. 비만과 당뇨병과 같은 생활습관병이 증가함에 따라 장기적인 심혈관 치료에 대한 수요도 증가하고 있습니다. 또한, 신흥국의 의료 접근성 확대로 더 많은 환자들이 진단과 치료를 받고 있으며, 암로디핀 베실산염과 같은 저렴한 제네릭 의약품에 대한 수요가 더욱 증가하고 있습니다.

그러나 시장 경쟁이 치열하고 수많은 제네릭 의약품 제조업체가 존재하기 때문에 가격 압력이 가해져 이익률이 줄어들고 있습니다. 특히 미국 및 EU 시장을 타겟으로 하는 수출업체에게는 의약품의 품질 및 제조 기준에 대한 규제 당국의 감시가 강화되는 것도 우려되는 부분입니다.

주요 시장 성장 촉진요인

헬스케어 분야의 성장:

주요 시장 과제:

병용요법으로의 전환:

주요 시장 동향 :

고혈압 유병률 증가:

목차

제1장 제품 개요

제2장 조사 방법

제3장 주요 요약

제4장 세계 암로디핀 베실산염 시장에 COVID-19가 주는 영향

제5장 세계의 암로디핀 베실산염 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 판매채널별(직접, 간접)
  • 최종 용도별(고혈압, 만성 안정 협심증, 혈관 경련성 협심증, 관상동맥 질환, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 암로디핀 베실산염 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 암로디핀 베실산염 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 암로디핀 베실산염 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 암로디핀 베실산염 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 암로디핀 베실산염 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)
• 제품 출시
• 최근 동향

제13장 세계의 암로디핀 베실산염 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Dr. Reddy's Laboratories Ltd.
• Plasma Labs Pvt. Ltd
• Changzhou Yabang Pharmaceutical Co., LTD.
• DECLAN INDUSTRIES PVT. LTD
• Kopalle Pharma Chemicals Private Limited
• Graddy Pharmachem
• PRUDENCE PHARM CHEM
• Unichem Laboratories Ltd
• Vineet Life Sciences Pvt. Ltd.
• Lupin Limited

제16장 전략적 제안

제17장 회사 소개 및 면책조항

영문목차

Global Amlodipine Besylate market was valued at USD 690.88 million in 2024 and is projected to reach USD 1,218.65 million by 2030, reflecting a compound annual growth rate (CAGR) of 4.25% during the forecast period. This market is experiencing steady growth, primarily driven by the increasing prevalence of hypertension and cardiovascular diseases. Amlodipine Besylate, a widely prescribed calcium channel blocker, is essential for managing high blood pressure and angina, making it a cornerstone of cardiovascular treatment worldwide. The primary market driver is the escalating global incidence of hypertension, particularly in aging populations. As lifestyle-related health conditions such as obesity and diabetes rise, the demand for long-term cardiovascular therapies is also growing. Additionally, with expanding healthcare access in emerging economies, more individuals are being diagnosed and treated, which further boosts demand for affordable generic alternatives like Amlodipine Besylate.

However, the market is highly competitive, with numerous generic manufacturers, leading to price pressure and shrinking profit margins. Increased regulatory scrutiny, particularly concerning drug quality and manufacturing standards, is also a growing concern, especially for exporters targeting the U.S. and EU markets.

Key Market Drivers:

Growth in the Healthcare Sector:

The continued expansion of the global healthcare industry is a significant growth driver for the Amlodipine Besylate market. With the healthcare industry generating annual revenues exceeding USD 4 trillion, the pharmaceutical and biotechnology sectors contribute nearly USD 850 billion, while medical technology and diagnostics account for over USD 400 billion. As nations continue to invest in strengthening their healthcare systems-enhancing infrastructure, expanding access to medical services, and adopting advanced treatment protocols-the demand for antihypertensive medications such as Amlodipine Besylate is steadily increasing. Amlodipine Besylate remains a key treatment for high blood pressure and coronary artery disease, solidifying its position in both developed and emerging markets.

Key Market Challenges:

Shift Towards Combination Therapies:

A notable challenge in the Amlodipine Besylate market is the increasing preference among healthcare providers for fixed-dose combination (FDC) therapies. With a greater focus on improving patient compliance and achieving better therapeutic outcomes, many physicians are recommending combination treatments that pair Amlodipine with other antihypertensive agents like ACE inhibitors, ARBs, or diuretics. These combination therapies offer the convenience of a single pill, reduce pill burden, and often provide enhanced blood pressure control, making them more attractive from a clinical perspective. As a result, the demand for Amlodipine Besylate as a standalone treatment is gradually decreasing. This shift presents a challenge for manufacturers focused on monotherapy formulations, as they may experience a decline in market share and will need to adjust their strategies to include or co-market combination products. Additionally, the higher regulatory and development costs associated with fixed-dose combinations could create barriers for smaller market participants, intensifying competition.

Key Market Trends:

Rising Hypertension Prevalence:

The increasing global prevalence of hypertension is a critical trend propelling the growth of the Amlodipine Besylate market. The World Health Organization (WHO) reported in 2023 that 1.28 billion adults aged 30 to 79 suffer from hypertension, with two-thirds of these individuals residing in low- and middle-income countries. A key global health goal is to reduce the prevalence of hypertension by 33% from 2010 to 2030. Often called the "silent killer," hypertension is one of the most widespread chronic conditions and a major risk factor for cardiovascular diseases, strokes, and kidney problems. The growing number of hypertension diagnoses, particularly in low- and middle-income nations, is significantly boosting the demand for effective antihypertensive treatments like Amlodipine Besylate. This trend is driven by demographic and lifestyle factors, including aging populations, sedentary behaviors, poor diets, rising obesity rates, and increased stress. As awareness and diagnostic capabilities improve, more individuals are being screened and treated, contributing to a larger patient base reliant on long-term pharmacological interventions.

Key Market Players

• Dr. Reddy's Laboratories Ltd.
• Plasma Labs Pvt. Ltd
• Changzhou Yabang Pharmaceutical Co., LTD.
• DECLAN INDUSTRIES PVT. LTD
• Kopalle Pharma Chemicals Private Limited
• Graddy Pharmachem
• PRUDENCE PHARM CHEM
• Unichem Laboratories Ltd
• Vineet Life Sciences Pvt. Ltd.
• Lupin Limited

Report Scope

In this report, the Global Amlodipine Besylate Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Amlodipine Besylate Market, By Sales Channel:

• Direct
• Indirect

Amlodipine Besylate Market, By End Use:

• Hypertension
• Chronic Stable Angina
• Vasospastic Angina
• Coronary Artery Disease
• Others

Amlodipine Besylate Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Amlodipine Besylate Market.

Available Customizations:

Global Amlodipine Besylate Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Amlodipine Besylate Market

5. Global Amlodipine Besylate Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By End Use (Hypertension, Chronic Stable Angina, Vasospastic Angina, Coronary Artery Disease, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Amlodipine Besylate Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Amlodipine Besylate Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Amlodipine Besylate Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Amlodipine Besylate Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By End Use

7. Europe Amlodipine Besylate Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Amlodipine Besylate Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Amlodipine Besylate Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Amlodipine Besylate Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Amlodipine Besylate Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Amlodipine Besylate Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By End Use

8. Asia Pacific Amlodipine Besylate Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Amlodipine Besylate Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Amlodipine Besylate Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Amlodipine Besylate Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Amlodipine Besylate Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Amlodipine Besylate Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By End Use

9. South America Amlodipine Besylate Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Amlodipine Besylate Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Amlodipine Besylate Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Amlodipine Besylate Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Amlodipine Besylate Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Amlodipine Besylate Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Amlodipine Besylate Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Amlodipine Besylate Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Amlodipine Besylate Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Dr. Reddy's Laboratories Ltd.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Plasma Labs Pvt. Ltd
• 15.3. Changzhou Yabang Pharmaceutical Co., LTD.
• 15.4. DECLAN INDUSTRIES PVT. LTD
• 15.5. Kopalle Pharma Chemicals Private Limited
• 15.6. Graddy Pharmachem
• 15.7. PRUDENCE PHARM CHEM
• 15.8. Unichem Laboratories Ltd
• 15.9. Vineet Life Sciences Pvt. Ltd.
• 15.10. Lupin Limited

16. Strategic Recommendations

17. About Us & Disclaimer